KeepHealthCare.ORG – Pharmalittle: Breast cancer patients need less of a Roche drug; China extends patent protection
ood morning, everyone, and how are you this morning? We are doing just fine, thank you, despite another spot of rain and accompanying gloomy clouds hovering over head. After all, our spirits remain sunny, thanks to that age-old reminder from the Morning Mayor: Every brand new day should be unwrapped like a precious gift. So while you ponder the notion and tug on the ribbon, here are a few tidbits to help you along the journey today. Hope all goes well and, of course, do keep in touch. We appreciate your phone calls, texts, dossiers, and telegrams …
Treating breast-cancer patients with an expensive Roche (RHHBY) drug for six months instead of 12 reduced heart-related side effects and its costs without sacrificing its effectiveness in preventing relapses, The Wall Street Journal writes, citing a new study. Funded by the U.K. National Institute for Health Research, the study was conducted on more than 4,000 women in the early stages of an aggressive type of breast cancer known as HER2-positive. Herceptin generated about $7 billion in global sales for Roche last year.
What is it?
Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
Subscriber-only networking events and panel discussions across the country
Monthly subscriber-only live chats with our reporters and experts in the field
Discounted tickets to industry events and early-bird access to industry reports
Pharmalot Columnist, Senior Writer
Ed covers the pharmaceutical industry.